During the past years transcatheter aortic valve implantation (TAVI) has evolved to a standard technique for
the treatment of high risk patients suffering from severe aortic stenosis. Worldwide the number of TAVI procedures is increasing
exponentially. In this context both the transapical antegrade (TA) and the transfemoral retrograde (TF) approach
are predominantly used and can be considered as safe and reproducible access sites for TAVI interventions. As a new
technology TAVI is in a constant progress regarding the development of new devices. While in the first years only the
Edwards SAPIENTM and the Medtronic CoreValveTM prostheses were commercial available, recently additional devices
obtained CE-mark approval and others have entered initial clinical trials. In addition to enhance the treatment options in
general, the main driving factor to further develop new device iterations is to solve the drawbacks of the current TAVI
systems: paravalvular leaks, occurrence of AV-blocks and the lack of full repositionability.
Keywords: Transapical, transfemoral, transcatheter aortic valve implantation, aortic valve stenosis.
Rights & PermissionsPrintExport